Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.54 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15317676 | 0.91 | SIGMAR1 (0.66) | HRH3SLC6A3SIGMAR1KDM4EDRD2 | |
| SCHEMBL15317686 | 0.86 | SIGMAR1 (0.57) | HRH3SLC6A3SIGMAR1 | |
| SCHEMBL25530953 | 0.85 | ACHE (0.63) | HRH3SIGMAR1 | |
| SCHEMBL25541600 | 0.84 | SPHK1 (0.50) | HRH3SIGMAR1 | |
| SCHEMBL12449567 | 0.83 | ALDH1A1 (0.69) | HRH3SIGMAR1KDM4EALDH1A1GAA | |
| SCHEMBL25530986 | 0.83 | HTR2A (0.46) | HRH3SIGMAR1KDM4E | |
| SCHEMBL271331 | 0.82 | ALDH1A1 (0.71) | HRH3SIGMAR1KDM4EALDH1A1GAA | |
| SCHEMBL25541603 | 0.82 | CARM1 (0.50) | HRH3SIGMAR1ALDH1A1GAA | |
| SCHEMBL1901538 | 0.81 | HRH3 (0.70) | HRH3SLC6A3SIGMAR1HTR1DHTR1B | |
| SCHEMBL25530955 | 0.81 | MEN1 (0.50) | HRH3SLC6A3DRD2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | HRH3 533/4885SLC6A3 4708/4885SIGMAR1 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.